Industry Watch [to 10 September 2016]
:: Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)
Study to evaluate vaccine protection against all four strains of dengue virus, regardless of previous exposure
September 07, 2016
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited today announced that it has vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study (TIDES), a Phase 3 double-blind, randomized and placebo-controlled trial of its live-attenuated tetravalent dengue vaccine candidate (TAK-003).

TIDES will enroll approximately 20,000 healthy children between the ages of four and 16 years living in dengue-endemic countries in Latin America and Asia. The study will evaluate the efficacy of the vaccine candidate to protect subjects against symptomatic dengue fever caused by any of the four dengue virus serotypes, regardless of age and whether the individual has previously been exposed to the virus. The study will also evaluate vaccine safety and immunogenicity and will involve two doses of the vaccine candidate or placebo administered 90 days apart.1 …

.

:: U.S. Biomedical Advanced Research and Development Authority (BARDA) Awards Protein Sciences Multi-Million Dollar Contract for Pandemic Preparedness
MERIDEN, Conn., Sept. 7, 2016 /PRNewswire/ — Protein Sciences Corporation announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, has awarded the Company a contract that is part of the Authority’s medical countermeasures against pandemic influenza and influenza strains with pandemic potential (contract number HHSO100201600005I). Protein Sciences will perform the contract using its proprietary platform technology for producing vaccines that according to the Food and Drug Administration has revolutionized influenza vaccine manufacturing and stands to receive up to $610 million through 2021 if BARDA exercises all options…

.

:: Gyeongbuk Kick-Starts Vaccine Industry with ‘Global Vaccine Industry Forum 2016’
– More than 200 experts from industry, academia, research institutes from Korea and abroad, including IVI, in attendance
– MOU between IVI, Gyeongbuk (province), Andong (city) signed; keynote speech, presentations, discussions delivered
– Officials from global vaccine enterprises including GSK, Sanofi Pasteur, Bill & Melinda Gates Foundation invited to attend
Gyeongsangbuk-do (Gyeongbuk or North Gyeongsang Province) held the opening ceremony of the ‘Gyeongbuk Global Vaccine Industry Forum 2016’ at Richell Hotel in Andong on September 9 to seek to set direction and strategy for development of the vaccine industry, form a network with domestic and overseas partners, and expedite mutual exchange in order to lay the foundation to nurture the vaccine industry.

Held under the theme “Present and Future of Globalization of the Korean Vaccine Industry,’ the forum is taking place on September 8 – 10. The opening ceremony on September 9 was a huge success, as it brought together more than 200 vaccine experts and officials including Gyeongbuk Governor Kim Kwan-yong, Rep. Kim Kim Gwang-lim, Andong Mayor Kwon Young-se, and Jerome Kim, Director General of the International Vaccine Institute…

.

:: DCVMN [Developing Country Vaccine Manufacturers Network] Annual General Meeting
24 October 2016 to 27 October 2016
Buenos Aires / / Argentina